INFO & CONTACTS:  +39 02 2390 1

A Phase 3 Open-Label Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, In Comparison with Standard of Care Platinum/Pembrolizumab/5-FU, in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase: Phase II-III clinical trials

Principal Investigator: Professoressa Associata Licitra Lisa Francesca Linda

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: Amivantamab

Pathologies: Other

ClinicalTrials.gov: Read the details about clinical trials

ORIGAMI-5 was designed to compare the efficacy and safety of subcutaneous amivantamab administered in combination with pembrolizumab and carboplatin (experimental arm) versus pembrolizumab combined with 5-fluorouracil (5-FU) and carboplatin or cisplatin (control arm) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 

The study specifically focuses on treatment-naïve patients in the recurrent/metastatic setting, defined as those who have not received prior systemic therapy for this stage of disease. 

Amivantamab, evaluated in the experimental arm, is a fully humanized bispecific IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR) and the mesenchymal–epithelial transition (MET) receptor. By acting on these two key pathways involved in tumor growth, it: 

  • inhibits signaling pathways that promote tumor cell proliferation 
  • may enhance immune-mediated destruction of cancer cells 

In this way, it may contribute to slowing or inhibiting tumor progression. 

The study, conducted in accordance with international ethical guidelines, is considered investigational because, although amivantamab was approved by AIFA in 2023 for the treatment of non-small cell lung cancer, it has not yet been approved by regulatory authorities for the treatment of head and neck cancers. However, the potential therapeutic role of the drug has been supported by previous clinical studies, providing biological and clinical rationale for its use in combination with immune checkpoint inhibitors to potentially improve outcomes in this patient population. 

An additional innovative aspect of the ORIGAMI study is the use of subcutaneous administration (injection under the skin) rather than intravenous infusion. 

The subcutaneous formulation offers several potential advantages: 

  • a lower incidence of infusion-related reactions 
  • a reduced risk of certain adverse events 
  • significantly shorter administration times, with efficacy comparable to the intravenous formulation 

In contrast, the other agents included in the study—5-FU, carboplatin or cisplatin, and pembrolizumab—have long been approved by the U.S. Food and Drug Administration (FDA) and by AIFA (Italian Medicines Agency) for the treatment of various malignancies. 

The primary objective of this study is to evaluate the antitumor activity and clinical efficacy of amivantamab in head and neck cancer. In particular, overall survival and treatment response will be assessed. 

Participation in the study occurs through randomization. Randomization is a computerized process that assigns patients to treatment groups at random, without any possibility of choice by either the investigator or the patient. There is a 1:1 probability of being assigned to either treatment group: 

  • Group A: pembrolizumab, carboplatin, and amivantamab 
  • Group B: pembrolizumab, platinum-based therapy (cisplatin or carboplatin, at the physician’s discretion), and 5-fluorouracil 

Eligibility for enrollment depends on patient characteristics (including demographic data, oncologic history, and comorbidities), laboratory findings, and radiologic parameters, which will be assessed through specific screening procedures prior to treatment initiation.  

Treatment will be administered as follows: 

  • Group A: Subcutaneous amivantamab weekly during the first cycle and every three weeks thereafter; pembrolizumab and carboplatin every three weeks. Carboplatin will be administered for a maximum of six cycles. 
  • Group B: Pembrolizumab, platinum-based therapy, and 5-FU administered via intravenous infusion every three weeks. Platinum and 5-FU will be administered for a maximum of six cycles. 

Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or as otherwise specified in the study protocol. Continuation of therapy beyond these conditions may occur at the investigator’s discretion and upon the patient’s voluntary decision, following signature of the appropriate consent for continuation of treatment, where applicable. 

Patients will be carefully monitored for chemotherapy-related adverse events as well as for potential immune-mediated toxicities, which may occur as a result of immune system overactivation induced by immunotherapy. In some cases, immunotherapy may lead to adverse events because the immune system may attack not only malignant cells but also healthy tissues. Should such events occur, investigators will implement appropriate management strategies, including symptomatic treatment and measures aimed at reducing toxicity (e.g., temporary treatment interruption, dose modification, corticosteroid therapy, or other supportive interventions). 

To ensure patient safety, all participants will be closely monitored throughout the study for treatment-related toxicities. 

The study staff are available to provide further information (email: amo@istitutotumori.mi.it) 

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe